# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $200 pric...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $200 pric...
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.0...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $200 pric...
Stifel analyst Dae Gon Ha reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $178 to $204.